Myung In Pharm received a one-month suspension of manufacturing operations from the Ministry of Food and Drug Safety (MFDS) for a liver disease treatment. The suspension runs from on the 20th to Dec. 19.
According to the MFDS on the 21st, Myung In Pharm manufactured the prescription drug "Levomels Injection" without following its own manufacturing control manual during production. This constitutes a violation of the Pharmaceutical Affairs Act, so the MFDS issued an administrative disposition. Levomels Injection is a prescription drug used for detoxification in severe liver disease.
The MFDS said, "When manufacturing medicines, pharmaceutical companies must manufacture precisely in accordance with the manufacturing control manual and product specifications, and must comply with the prepared manuals and instructions."